UBS raised the firm’s price target on Syndax (SNDX) to $38 from $35 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Strong Growth Potential and Market Expansion Justify Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals: Strategic Advancements and Growth Potential Reinforce Buy Rating
- Syndax price target raised to $22 from $19 at Barclays
- Syndax Pharmaceuticals Reports Strong Q3 2025 Growth
- Syndax reports Q3 EPS (70c), consensus (71c)